Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept maintenance in mCRC
NCT02129257Phase 2Completed
- Sponsor
- HeCOG
- Start
- May 2014
- Primary completion
- Jan 2017
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in colorectal cancer (metastatic) (mCRC), sponsored by HeCOG. Started May 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT02129257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129257.